Latest news of the coronavirus, live | The Carlos III study concludes that a second dose with Pfizer is more protective for those vaccinated with AstraZeneca

Note to readers: EL PAÍS openly offers essential information on the coronavirus during the crisis. If you want to support our journalism, subscribe here.

The Carlos III Health Institute has released the results of a study with 600 volunteers on the efficacy of administering a dose of the Pfizer vaccine to those under 60 who received a first dose of AstraZeneca. The institute considers this method to be “highly safe”, and that a second dose with Pfizer offers more protection for those vaccinated with a first dose of AstraZeneca than receiving a second dose from AstraZeneca. “It has been seen in the trials with two doses of AstraZeneca is that the level of neutralizing antibodies is three times. What we have seen in our study is that the increase is more than seven times ”, indicated Dr. María Teresa Pérez. 400 volunteers were inoculated with a dose of the Pfizer cocktail. Another 200, the control group, did not receive a second dose of any vaccine. In Spain, 60-year-olds have received, above all, the AstraZeneca vaccine, and will receive the second dose of this same pharmaceutical. Last April, Health temporarily suspended vaccination with AstraZeneca for those under 60 years of age. The Public Health Commission meets Tuesday to decide how it will immunize the nearly two million children under 60 who received a first dose of the AstraZeneca vaccine. .

Leave a Reply

Your email address will not be published. Required fields are marked *